Fulcrum Therapeutics, Inc.
FULC· Nasdaq
FULCFulcrum Therapeutics, Inc.
Filed Feb 25, 2025 · 10-K · 56 days after period end · 0000950170-25-026068
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $871.00K | $295.00K | $2.59M |
| Net Income | -$16.57M | -$24.76M | -$24.78M | -$25.93M |
| EPS Diluted | — | — | -$0.41 | -$0.64 |
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Feb 25, 2025 · 56 d after period end
